Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies

Hiroaki Araie, Yuka Kawaguchi, Motohito Okabe, Yoonha Lee, Marie Ohbiki, Masahide Osaki, Miyo Goto, Tatsunori Goto, Takanobu Morishita, Yukiyasu Ozawa, Koichi Miyamura

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Malnutrition before allogeneic hematopoietic cell transplantation (allo-HCT) is associated with poor clinical outcomes. Herein, we evaluated the predictive value of controlling nutritional status (CONUT) in patients undergoing allo-HCT for myeloid malignancies. We retrospectively analyzed 200 patients with myeloid malignancies who underwent allo-HCT for the first time. We evaluated CONUT before the initiation of conditioning and compared malnourished patients (poor CONUT, n = 56) with non-malnourished patients (normal CONUT, n = 144). The cumulative incidence of non-relapse mortality within 100 days (early NRM) was significantly higher in the poor CONUT group than in the normal CONUT group [21.4% (95% CI: 11.8–33.0%) vs. 9.7% (95% CI: 5.6–15.2%); P = 0.025]. In multivariate analysis, poor CONUT was an independent and significant risk factor for early NRM [HR: 2.2 (95% CI: 1.0–4.7); P = 0.048]. The overall 1-year survival rate was significantly lower in the poor CONUT group than in the normal CONUT group [53.3% (95% CI: 39.4–65.4%) vs. 71.0% (95% CI: 62.7–77.7%); P = 0.005]. These findings suggest that CONUT before allo-HCT is a useful predictor of poor outcomes in patients with myeloid malignancies.

Original languageEnglish
Pages (from-to)599-605
Number of pages7
JournalInternational Journal of Hematology
Volume110
Issue number5
DOIs
Publication statusPublished - 01-11-2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'Prediction of clinical outcome by controlling nutritional status (CONUT) before allogeneic hematopoietic stem cell transplantation in myeloid malignancies'. Together they form a unique fingerprint.

Cite this